Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial
Top Cited Papers
- 1 October 2000
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet
- Vol. 356 (9237), 1213-1218
- https://doi.org/10.1016/s0140-6736(00)02783-5
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Vitamin E and heart disease:: Basic science to clinical intervention trialsFree Radical Biology & Medicine, 2000
- Vitamin E Supplementation and Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- Controlled Trial of α-Tocopherol and β-Carotene Supplements on Stroke Incidence and Mortality in Male SmokersArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- Comparison of hemostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patientsAmerican Journal of Kidney Diseases, 1999
- Serum malondialdehyde and prevalent cardiovascular disease in hemodialysisKidney International, 1999
- Antioxidants and Atherosclerotic Heart DiseaseNew England Journal of Medicine, 1997
- Which Diet for Which Renal Failure: Making Sense of the OptionsJournal of the American Dietetic Association, 1995
- Cardiac function and hematocrit levelAmerican Journal of Kidney Diseases, 1995
- Effect of hemodialysis on lipid peroxidation and antioxidant system in patients with chronic renal failureMetabolism, 1992
- [35] Comparative studies on different methods of malonaldehyde determinationMethods in enzymology, 1984